SCHEDULE: Highbridge Capital Management Reports Minimal Stake in Aspire Biopharma

Highbridge Capital Management, LLC has filed a Schedule 13G, reporting beneficial ownership of 78 shares of Aspire Biopharma Holdings, Inc. common stock, representing 0.0% of the class.

Summary

• Highbridge Capital Management, LLC has filed an amendment to its Schedule 13G filing.
• The filing pertains to Aspire Biopharma Holdings, Inc. common stock.
• Highbridge Capital Management, LLC is reporting beneficial ownership of 78 shares of common stock.
• These shares are issuable upon the exercise of warrants held by Highbridge Funds.
• The reported ownership represents 0.0% of the class of securities.
• The filing date is June 30, 2026, with the report date being August 14, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the minimal ownership percentage and the nature of the filing as a Schedule 13G, indicating passive investment rather than active strategic interest.

Negatives

• The reported beneficial ownership is a negligible 78 shares, equating to 0.0% of the outstanding class of securities.
• The filing indicates a passive investment approach rather than a significant strategic stake.

Risks

• The filing does not detail specific risks related to Aspire Biopharma Holdings, Inc. itself, but the minimal stake by Highbridge Capital Management suggests a lack of strong conviction in the company's future prospects from this investor.

Future Outlook

The filing does not contain forward-looking statements or guidance from Highbridge Capital Management regarding Aspire Biopharma Holdings, Inc.

Management Comments

• The filing should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment by institutional investors. A 0.0% ownership stake, even if derived from warrants, suggests a very limited or speculative interest in Aspire Biopharma Holdings, Inc. from Highbridge Capital Management.

Stakeholder Impact

• Shareholders of Aspire Biopharma Holdings, Inc. may view the minimal stake reported by Highbridge Capital Management as a lack of strong institutional support or confidence in the company's immediate future.

Key Dates

Keywords

Aspire Biopharma Holdings, Highbridge Capital Management, Schedule 13G, Warrants, Beneficial Ownership, SEC Filing